[go: up one dir, main page]

AR053228A1 - Derivados de azol en calidad de inibidores de lipasas y fosfolipasas - Google Patents

Derivados de azol en calidad de inibidores de lipasas y fosfolipasas

Info

Publication number
AR053228A1
AR053228A1 ARP060101521A ARP060101521A AR053228A1 AR 053228 A1 AR053228 A1 AR 053228A1 AR P060101521 A ARP060101521 A AR P060101521A AR P060101521 A ARP060101521 A AR P060101521A AR 053228 A1 AR053228 A1 AR 053228A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
alkylene
aminocarbonyl
nr2r3
Prior art date
Application number
ARP060101521A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053228(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR053228A1 publication Critical patent/AR053228A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicacion 1: un compuesto de formula (1) en donde A es S, O; W es -(C=O)-, -(S=O)-, -(SO2)-; X es, de manera idéntica o diferente, =C(-R) o =N-; Y es -O- o -NR1-; R es H, halogeno, alquilo C1-6, alquiloxi C1-3-alquileno C1-3, hidroxi, alquil C1- 6-mercapto, amino, alquil C1-6-amino, di-alquil C2-12-amino, mono-alquil C1-6-aminocarbonilo, di-alquil C2-6-aminocarbonilo, COOR4, trifluorometilo, alquil C1-6-sulfonilo, alquil C1-6-sulfinilo, aminosulfonilo, nitro, pentafluorosulfanilo, arilo C6- 10, CO-NR2R3, O-CO-NR2R3, O-CO-alquileno C1-6, -CO-O-alquilo C1-6, O-CO-alquileno C1-6-CO-OH, O-CO-alquileno C1-6-CO-NR2R3 o alquiloxi C1-6 no sustituido o mono- o polisustituido con F; R1 es H, alquilo C1-6, bencilo; R2 es alquilo C5-16, alquil C1- 4-arilo C6-10, en que arilo puede estar opcionalmente sustituido, una o más veces, con halogeno, alquilo C1-6, alquiloxi C1-3, hidroxi, alquil C1-6-mercapto, amino, alquilo C1-6-amino, di-alquil C2-12-amino, mono-alquil C1-6-aminocarbonilo, di- alquil C2-8-aminocarbonilo, alcoxi C1-6-carbonilo, ciano, trifluorometilo trifluorometiloxi, alquil C1-6-sulfonilo, aminosulfonilo, nitro,; R3 es H, alquilo C1-6; o R2 y R3, junto con el átomo de N que los porta, pueden formar un sistema de anillo de 4 a 7 miembros, monocíclico, saturado o parcialmente insaturado, o un sistema de anillo de 8 a 14 miembros, bicíclico, saturado parcialmente insaturado, cuyos miembros individuales de los sistemas de anillo pueden estar reemplazados por uno a tres átomos o grupos atomicos de las series -CHR5, -CR5R5-, -(C=R5)-, -NR5-, -C(=O)-, -O-, -S-, -SO-, -SO2-, con la condicion de que dos unidades de las series -O-, -S-, -SO-, -SO2-, no pueden estar adyacentes; R4 es h, alquilo C1-6, bencilo; R5 es alquilo C1-6, halogeno, trifluorometilo, COOR4, ciclopropilo, ciclopropileno, las formas tautomeras de los compuestos y las sales fisiologicamente toleradas de los mismos.
ARP060101521A 2005-04-20 2006-04-18 Derivados de azol en calidad de inibidores de lipasas y fosfolipasas AR053228A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005018389A DE102005018389A1 (de) 2005-04-20 2005-04-20 Azolderivate als Inhibitoren von Lipasen und Phospholipasen

Publications (1)

Publication Number Publication Date
AR053228A1 true AR053228A1 (es) 2007-04-25

Family

ID=36694158

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101521A AR053228A1 (es) 2005-04-20 2006-04-18 Derivados de azol en calidad de inibidores de lipasas y fosfolipasas

Country Status (20)

Country Link
US (1) US8921404B2 (es)
EP (1) EP1874741A1 (es)
JP (1) JP2008536884A (es)
KR (1) KR20080004501A (es)
CN (1) CN101160293A (es)
AR (1) AR053228A1 (es)
AU (1) AU2006237127A1 (es)
BR (1) BRPI0608495A2 (es)
CA (1) CA2606301A1 (es)
DE (1) DE102005018389A1 (es)
IL (1) IL186635A0 (es)
MA (1) MA29393B1 (es)
MX (1) MX2007012732A (es)
MY (1) MY142441A (es)
NO (1) NO20075938L (es)
NZ (1) NZ562694A (es)
RU (1) RU2414458C2 (es)
TW (1) TW200722421A (es)
WO (1) WO2006111321A1 (es)
ZA (1) ZA200707929B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
KR20090127418A (ko) 2007-04-05 2009-12-11 사노피-아벤티스 리파제 및 포스포리파제의 억제제로서의 5-옥소-이속사졸
RU2009140761A (ru) 2007-04-05 2011-05-10 Санофи-Авентис (Fr) Производные амида имидазолидинкарбоновой кислоты в качестве ингибиторов липаз и фосфолипаз
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
EP2351744B1 (en) * 2008-10-17 2015-01-07 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
KR20120123325A (ko) 2009-12-15 2012-11-08 시오노기세야쿠 가부시키가이샤 혈관 내피 리파아제 저해 활성을 갖는 옥사디아졸 유도체
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション PPARδアゴニストの胎児再プログラミング用途
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN108349997B (zh) * 2015-08-27 2025-06-10 奥克兰联合服务有限公司 色氨酸双加氧酶(ido1和tdo)抑制剂及其在治疗中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221138B1 (en) * 1994-08-30 2002-08-28 Sankyo Co Condensed isoxazolyloxy- and -thioalkylamine derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
AU2002226633A1 (en) * 2001-02-02 2002-08-12 Pfizer Limited Treatment of diabetes mellitus using vardenafil
AU2001274426A1 (en) 2001-07-04 2003-01-21 Akodi S.A. Web windowed graphical user interface
JP2003033007A (ja) 2001-07-09 2003-01-31 Sanyo Electric Co Ltd チャージポンプ回路の制御方法
EP1458374A2 (en) * 2001-12-14 2004-09-22 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
WO2004058749A1 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
EP1615900A1 (en) * 2003-04-01 2006-01-18 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
EP1613608A1 (en) * 2003-04-01 2006-01-11 Eli Lilly And Company Phospholipase inhibitors
JP2007529468A (ja) * 2004-03-16 2007-10-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイソオキサゾール
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound

Also Published As

Publication number Publication date
DE102005018389A1 (de) 2006-10-26
JP2008536884A (ja) 2008-09-11
WO2006111321A1 (de) 2006-10-26
IL186635A0 (en) 2008-01-20
MX2007012732A (es) 2008-03-14
KR20080004501A (ko) 2008-01-09
RU2007142657A (ru) 2009-05-27
NO20075938L (no) 2007-11-19
CN101160293A (zh) 2008-04-09
AU2006237127A1 (en) 2006-10-26
ZA200707929B (en) 2008-12-31
US20080090867A1 (en) 2008-04-17
NZ562694A (en) 2010-05-28
BRPI0608495A2 (pt) 2010-01-05
US8921404B2 (en) 2014-12-30
EP1874741A1 (de) 2008-01-09
MA29393B1 (fr) 2008-04-01
MY142441A (en) 2010-11-30
TW200722421A (en) 2007-06-16
RU2414458C2 (ru) 2011-03-20
CA2606301A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
AR053228A1 (es) Derivados de azol en calidad de inibidores de lipasas y fosfolipasas
AR056686A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas
AR047456A1 (es) Derivados de amidas, procesos para su preparacion y uso como insecticidas
AR047520A1 (es) Derivados de indazol como inhibidores de la lipasa sensible a hormonas
CR10611A (es) Isoxazolinas insecticidas
CY1123801T1 (el) Παραγωγα αρωματικου σουλφοναμιδιου
EP3955870C0 (en) EXCIMER LASER FIBER LIGHTING
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR073138A1 (es) Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol
AR058095A1 (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas. procesos de obtencion y composiciones farmaceuticas.
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
DK3625233T5 (da) 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoat-derivativer og relaterede forbindelser som peroralt indgivne prodrugs af beta-lactamase-inhibitorer til behandling af bakterielle infektioner
ECSP067098A (es) Compuestos y metodos para el tratamiento de dislipidemia
ES2655091T3 (es) Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos
AR071902A1 (es) 4-(3-alquilsulfinilbenzoil)pirazoles utiles como agentes herbicidas y procedimiento para combatir plantas indeseadas.
EA201891780A1 (ru) Производные сульфонамида и содержащие их фармацевтические композиции
AR076610A1 (es) Compuestos spiro epoxidos como intermediarios
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR066077A1 (es) Tiadiazoliloxifenilamidinas y su uso como fungicidas
AR048086A1 (es) Bencenodicarboxamidas insecticidas
BR112021022613A2 (pt) Métodos de fabricação de canabidiol ou canabidivarina e intermediários de fabricação de canabidiol ou canabidivarina
PE20221006A1 (es) Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7

Legal Events

Date Code Title Description
FA Abandonment or withdrawal